a double blind study comparing two doses of iv esomeprazole after successful endoscopic therapy

Conditions: Upper Gastrointestinal Bleeding

Summary: a bleeding peptic ulcer remains a serious medical problem with significant morbidity and mortality. endoscopic therapy significantly reduces further bleeding, surgery, and mortality in patients with bleeding peptic ulcers and is now recommended as the first hemostatic modality for these patients. in the past few years, adjuvant use of a high-dose proton pump inhibitor (ppi) after endoscopic therapy has been endorsed in some studies. however, low dose of ppi has also been supported in the management of these patients. the investigators enroll 130 patients with active bleeding or nonbleeding visible vessels in this study. they are randomly assigned as 40 mg/day or 160mg/day iv nexium group. all patients receive successful endoscopic therapy with heater probe or hemoclip placement. in the low dose group (n=65), 40 mg iv nexium daily is given for three days. thereafter, the patients receive 40 mg nexium orally daily for two months. in the large dose group (n=65), 160 mg/day continuous infusion is given for three days. thereafter, the patients receive 40 mg nexium orally daily for two months. the primary end point is recurrent bleeding before discharge and within 14 days. at day 14, volume of blood transfused, number of surgeries performed, and the mortality rates of the two groups are compared as well.

a bleeding peptic ulcer remains a serious medical problem with significant morbidity and mortality. endoscopic therapy significantly reduces further bleeding, surgery, and mortality in patients with bleeding peptic ulcers and is now recommended as the first hemostatic modality for these patients. in the past few years, adjuvant use of a high-dose proton pump inhibitor (ppi) after endoscopic therapy has been endorsed in some studies. however, low dose of ppi has also been supported in the management of these patients. we enroll 130 patients with active bleeding or nonbleeding visible vessels in this study. they are randomly assigned as 40 mg/day or 160mg/day iv nexium group. all patients receive successful endoscopic therapy with heater probe or hemoclip placement. in the low dose group (n=65), 40 mg iv nexium daily is given for three days. thereafter, the patients receive 40 mg nexium orally daily for two months. in the large dose group (n=65), 160 mg/day continuous infusion is given for three days. thereafter, the patients receive 40 mg nexium orally daily for two months. the primary end point is recurrent bleeding before discharge and within 14 days. at day 14, volume of blood transfused, number of surgeries performed, and the mortality rates of the two groups are compared as well.

Eligibility criteria:
inclusion criteria: * a peptic with active bleeding, a non-bleeding visible vessel or an adherent blood clot at the ulcer base is observed within24 hours of hospital admission exclusion criteria: * patients are excluded from the study if they are pregnant, do not obtain initial hemostasis with endoscopic injection epinephrine, do not give written informed consent,have bleeding tendency(platelet count \<50\*109/l,serum prothrombin \<30% of normal, or were taking anticoagulants), uremia